Literature DB >> 5440784

Encephalopathy after portacaval shunting managed with lactulose.

H Brown, C Trey, W V McDermott.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1970        PMID： 5440784     DOI： 10.1016/0002-9610(70)90024-3

Source DB:  PubMed          Journal:  Am J Surg        ISSN： 0002-9610            Impact factor:   2.565


× No keyword cloud information.
  5 in total

Review 1.  Lactulose: a review of its therapeutic and pharmacological properties with particular reference to ammonia metabolism and its mode of action of portal systemic encephalopathy.

Authors:  G S Avery; E F Davies; R N Brogden
Journal:  Drugs       Date:  1972       Impact factor: 9.546

2.  Subtotal portacaval shunt obliteration for chronic hepatic encephalopathy.

Authors:  G S Kakos; W E Evans; M Czuba; J Spiegel; N J Greenberger
Journal:  Ann Surg       Date:  1973-03       Impact factor: 12.969

Review 3.  Portacaval shunts.

Authors:  A D Callow
Journal:  World J Surg       Date:  1984-10       Impact factor: 3.352

Review 4.  Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis.

Authors:  Lise Lotte Gluud; Hendrik Vilstrup; Marsha Y Morgan
Journal:  Cochrane Database Syst Rev       Date:  2016-05-06

5.  Faecal ammonia and pH during lactulose administration in man: comparison with other cathartics.

Authors:  L Agostini; P F Down; J Murison; O M Wrong
Journal:  Gut       Date:  1972-11       Impact factor: 23.059
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.